UK Government Funds Expanded Prostate Cancer Screening Trial for Black Men
The UK government has announced an expansion of the Transform trial, extending invitations for prostate cancer checks to tens of thousands more Black men aged 45-74. This initiative, supported by an £18 million investment, seeks to identify more effective screening methods for the disease, acknowledging the disproportionately higher risk faced by Black men.
Prostate cancer is the most prevalent cancer among men in the UK, with approximately 64,000 diagnoses and 12,000 deaths annually. While the lifetime risk for men generally stands at one in eight, this doubles to one in four for Black men.
This expansion comes despite a recent recommendation from the UK National Screening Committee against routine prostate-specific antigen (PSA) testing for most men. The committee concluded that the potential harms of widespread PSA screening, such as overtreatment leading to bladder control issues or erectile dysfunction, often outweigh the benefits. Some prostate tumours may never become life-threatening, making immediate treatment unnecessary.
The Transform trial is assessing whether advanced tests, including genetic analyses and expedited MRI scans, can enhance the accuracy of screening beyond the standard PSA test. All Black men aged 45-74 who have not recently undergone a PSA test will be offered participation, with the government stating the trial will contribute to establishing a more efficacious future screening system.
Health Secretary James Murray stated, “This is a major step forward in how we tackle prostate cancer - focusing on those most at risk, improving the treatments available, and backing the research we need to close the evidence gaps and save lives.” Charities and campaigners have welcomed the government’s decision as a “truly historic moment,” highlighting its potential to reach more Black men with vital information.
